0001415889-24-015088.txt : 20240531 0001415889-24-015088.hdr.sgml : 20240531 20240531180018 ACCESSION NUMBER: 0001415889-24-015088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GAROFALO ELIZABETH A. CENTRAL INDEX KEY: 0001826361 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 241011309 MAIL ADDRESS: STREET 1: C/O ACADIA PHARMACEUTICALS INC. STREET 2: 12830 EL CAMINO REAL, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-05312024_060514.xml X0508 4 2024-05-29 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001826361 GAROFALO ELIZABETH A. C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 true false false false 0 Common Stock 2024-05-29 4 M 0 6652 A 22514 D Restricted Stock Units 2024-05-29 4 M 0 6652 0 D Common Stock 6652 0 D Director Stock Options (Right to Buy) 14.62 2024-05-29 4 A 0 15959 0 A 2034-05-28 Common Stock 15959 15959 D Restricted Stock Units 2024-05-29 4 A 0 9387 0 A Common Stock 9387 9387 D Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. /s/ Jennifer J. Rhodes, Attorney-in-Fact 2024-05-31 EX-24 2 ex24-05312024_060514.htm ex24-05312024_060514.htm

POWER OF ATTORNEY



Know all by these presents, that the undersigned hereby authorizes each of Jennifer J. Rhodes, Peter Chae, James K. Kihara or Martin Choy to execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Acadia Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company.  The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.


This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 6th day of February 2024.



/s/ Elizabeth A. Garofalo

Elizabeth A. Garofalo




297519978 v1